Breaking News Instant updates and real-time market news.

MACK

Merrimack

$5.66

0.18 (3.28%)

07:33
10/11/16
10/11
07:33
10/11/16
07:33

Merrimack reports final results of Phase 3 NAPOLI-1 study of ONIVYDE

Merrimack Pharmaceuticals announced final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE in combination with fluorouracil and leucovorin, which represents a new standard of care for patients with metastatic pancreatic ductal adenocarcinoma following treatment with gemcitabine-based therapy. The final NAPOLI-1 results were presented in a poster discussion session and a separate analysis of NAPOLI-1 safety-over-time data was presented in a poster session at the European Society for Medical Oncology 2016 Congress in Copenhagen. "The final results of the NAPOLI-1 study provide a high level of clinical evidence establishing the ONIVYDE regimen as a meaningful treatment option for patients with metastatic pancreatic cancer," said Prof. Li-Tzong Chen, M.D., Ph.D., corresponding author, Investigator on the NAPOLI-1 trial and Director, National Institute of Cancer Research, National Health Research Institutes in Tainan, Taiwan. "Pancreatic cancer is a devastating disease with a poor prognosis. In a patient population with few treatment options, the ONIVYDE regimen provides an opportunity for extended overall survival while maintaining baseline quality-of-life and represents a new standard of care. We thank all of the patients, caregivers and investigators who participated in this pivotal study." The extended data cutoff occurred at final database lock in November 2015 after 382 OS events that had occurred in the intention-to-treat (ITT) population. In this extended analysis of NAPOLI-1, the previously described overall survival advantage was maintained for ONIVYDE in combination with 5-FU and leucovorin versus 5-FU and leucovorin alone: 6.2 months versus 4.2 months (p=0.039, hazard ratio (HR) =0.75, 95% CI: [.057 - .99]). Findings also showed that one in four patients treated with the ONIVYDE combination regimen survived one year or more, a significant milestone. This was represented by a 26% probability of survival at one year for patients receiving ONIVYDE in combination with 5-FU and leucovorin versus 16% for patients who received 5-FU and leucovorin alone. Furthermore, disease control was achieved in twice as many patients treated with ONIVYDE in combination with 5-FU and leucovorin (52%) compared to 5-FU and leucovorin alone (24%). The demonstrated improvements in overall survival for the ONIVYDE combination regimen were achieved with little or no impact on quality of life over 12 weeks despite the addition of a second chemotherapeutic agent to 5-FU and leucovorin, a therapy recognized as a well-managed treatment for metastatic pancreatic cancer. Results from a separate analysis of the NAPOLI-1 data evaluating the incidence and prevalence of gastrointestinal toxicities and neutropenia during the course of treatment with ONIVYDE plus 5-FU and leucovorin showed that the majority of these adverse events occurred early in treatment with decreased incidence and severity thereafter. Dose reductions or dose delays were commonly used to manage these adverse events and may account for the decreased incidence and/or severity that was observed.

MACK Merrimack
$5.66

0.18 (3.28%)

08/05/16
BMUR
08/05/16
NO CHANGE
Target $13
BMUR
Buy
Merrimack price target lowered to $13 from $16 at Brean Capital
Brean Capital lowered its price target on Merrimack to $13 from $16 following Q2 results. The firm cited the sales miss on Onivyde, although they are encouraged by its early launch. Brean Capital reiterated its Buy rating on Merrimack shares.
08/05/16
COWN
08/05/16
DOWNGRADE
COWN
Market Perform
Merrimack downgraded to Market Perform from Outperform at Cowen
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Merrimack initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Merrimack with a Neutral as he expects shares to be range-bound given the likely slow ramp-up of ONIVYDE and data from MM-302 and MM-121 won't be available until 2017 or beyond;
10/07/16
JPMS
10/07/16
DOWNGRADE
Target $7
JPMS
Neutral
Merrimack downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Merrimack Pharmaceuticals to Neutral saying the shares are likely to be range-bound after rallying 36% from the 52-week low on September 20. Key pipeline catalysts aren't likely until Q2 of 2017 and beyond while 2016 estimates are not "meaningfully beatable," Rama tells investors in a research note. He lowered his price target for the shares to $7 from $8.

TODAY'S FREE FLY STORIES

NVS

Novartis

$87.21

0.21 (0.24%)

, CMCSA

Comcast

$42.44

-0.45 (-1.05%)

20:25
01/23/18
01/23
20:25
01/23/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$87.21

0.21 (0.24%)

CMCSA

Comcast

$42.44

-0.45 (-1.05%)

GE

General Electric

$16.89

0.72 (4.45%)

UTX

United Technologies

$136.03

0.82 (0.61%)

ABT

Abbott

$59.23

-0.34 (-0.57%)

GD

General Dynamics

$207.48

-0.72 (-0.35%)

ITW

Illinois Tool Works

$173.06

-0.33 (-0.19%)

NSC

Norfolk Southern

$151.66

0.19 (0.13%)

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

PGR

Progressive

$57.05

-1.17 (-2.01%)

RCL

Royal Caribbean

$127.22

-1.48 (-1.15%)

SWK

Stanley Black & Decker

$173.89

-1.34 (-0.76%)

ROK

Rockwell Automation

$204.69

0.76 (0.37%)

NTRS

Northern Trust

$106.89

-0.54 (-0.50%)

GWW

Grainger

$229.45

-0.41 (-0.18%)

ROL

Rollins

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 08

    Feb

  • 16

    Feb

  • 02

    Mar

  • 23

    Apr

  • 17

    May

CERS

Cerus

$4.33

0.14 (3.34%)

19:39
01/23/18
01/23
19:39
01/23/18
19:39
Conference/Events
Cerus to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Feb

XPER

Xperi

$22.85

0.35 (1.56%)

19:26
01/23/18
01/23
19:26
01/23/18
19:26
Conference/Events
Xperi to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$7.86

-0.1 (-1.26%)

19:14
01/23/18
01/23
19:14
01/23/18
19:14
Upgrade
McDermott rating change at KeyBanc »

McDermott upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

, ERJ

Embraer

$24.13

-0.34 (-1.39%)

19:08
01/23/18
01/23
19:08
01/23/18
19:08
Periodicals
Bombardier invokes Embraer in Boeing trade dispute, Globe and Mail says »

Bombardier (BDRBF) says…

BDRBF

Bombardier

ERJ

Embraer

$24.13

-0.34 (-1.39%)

BA

Boeing

$335.59

-2.41 (-0.71%)

DAL

Delta Air Lines

$59.93

-0.2 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

GSBC

Great Southern Bancorp

$52.00

0.45 (0.87%)

19:01
01/23/18
01/23
19:01
01/23/18
19:01
Earnings
Great Southern Bancorp reports preliminary Q4 EPS 86c, consnesus 83c »

Reports preliminary Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

UUUU

Energy Fuels

$1.72

0.035 (2.08%)

18:48
01/23/18
01/23
18:48
01/23/18
18:48
Hot Stocks
Energy Fuels names Mark S. Chalmers president and CEO »

Energy Fuels announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

18:15
01/23/18
01/23
18:15
01/23/18
18:15
General news
Breaking General news story  »

Chicago Federal Reserve…

RBS

RBS

$8.46

-0.02 (-0.24%)

18:10
01/23/18
01/23
18:10
01/23/18
18:10
Periodicals
RBS plans to leave London headquarters by end of 2019, Reuters reports »

The Royal Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROX

Tronox

$21.88

0.07 (0.32%)

18:09
01/23/18
01/23
18:09
01/23/18
18:09
Hot Stocks
Tronox files lawsuit to prevent FTC from blocking proposed Cristal acquisition »

Tronox filed a lawsuit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNK

United Financial

$17.92

-0.03 (-0.17%)

18:00
01/23/18
01/23
18:00
01/23/18
18:00
Hot Stocks
United Financial reports Q4 provision for loan losses $2.3M »

Reports Q4 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UBNK

United Financial

$17.92

-0.03 (-0.17%)

17:59
01/23/18
01/23
17:59
01/23/18
17:59
Earnings
United Financial reports Q4 EPS with items 19c, consensus 30c »

Companies must recognize…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SPY

SPDR S&P 500 ETF Trust

$283.29

0.6 (0.21%)

, SPX

S&P 500

17:55
01/23/18
01/23
17:55
01/23/18
17:55
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Senate confirms Jerome…

SPY

SPDR S&P 500 ETF Trust

$283.29

0.6 (0.21%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:55
01/23/18
01/23
17:55
01/23/18
17:55
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

HESM

Hess Midstream Partners

$21.75

0.45 (2.11%)

17:46
01/23/18
01/23
17:46
01/23/18
17:46
Hot Stocks
Hess Midstream Partners raises quarterly dividend 3.6% to 32.2c per unit »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Feb

GWB

Great Western

$44.29

0.53 (1.21%)

17:33
01/23/18
01/23
17:33
01/23/18
17:33
Hot Stocks
Great Western announces financial impact resulting from Tax Cuts and Jobs Act »

Great Western Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

ARAY

Accuray

$5.20

0.05 (0.97%)

, TSS

TSYS

$83.92

0.17 (0.20%)

17:27
01/23/18
01/23
17:27
01/23/18
17:27
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

ARAY

Accuray

$5.20

0.05 (0.97%)

TSS

TSYS

$83.92

0.17 (0.20%)

CERS

Cerus

$4.33

0.14 (3.34%)

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

GOOG

Alphabet

$1,169.97

14.16 (1.23%)

GOOGL

Alphabet Class A

$1,176.17

12.01 (1.03%)

QGEN

Qiagen

$33.55

0.5 (1.51%)

SIRI

SiriusXM

$5.68

0.03 (0.53%)

VLO

Valero

$98.69

-0.26 (-0.26%)

UAL

United Continental

$77.97

1.1 (1.43%)

NAVI

Navient

$13.44

-0.08 (-0.59%)

CREE

Cree

$35.02

-1.67 (-4.55%)

COF

Capital One

$105.71

0.22 (0.21%)

TXN

Texas Instruments

$119.89

0.45 (0.38%)

PBYI

Puma Biotechnology

$90.90

-3.05 (-3.25%)

SIGM

Sigma Designs

$7.00

0.025 (0.36%)

FPRX

Five Prime

$22.43

0.14 (0.63%)

RCKT

Rocket Pharmaceuticals

$15.19

1.92 (14.47%)

TK

Teekay Corp.

$10.74

0.05 (0.47%)

SBBP

Strongbridge Biopharma

$8.70

0.25 (2.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    Mar

  • 21

    Mar

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

UAL

United Continental

$77.97

1.11 (1.44%)

17:25
01/23/18
01/23
17:25
01/23/18
17:25
Earnings
United Continental sees FY18 EPS $6.50-$8.50, consensus $6.97 »

Sees FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

17:25
01/23/18
01/23
17:25
01/23/18
17:25
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

MULE

MuleSoft

$25.08

-0.31 (-1.22%)

17:21
01/23/18
01/23
17:21
01/23/18
17:21
Initiation
MuleSoft initiated at Nomura Instinet »

MuleSoft initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MDB

MongoDB

$28.83

0.02 (0.07%)

17:19
01/23/18
01/23
17:19
01/23/18
17:19
Initiation
MongoDB initiated at Nomura Instinet »

MongoDB initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$77.97

1.1 (1.43%)

17:19
01/23/18
01/23
17:19
01/23/18
17:19
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United sees FY19 and FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

UAL

United Continental

$77.97

1.1 (1.43%)

17:18
01/23/18
01/23
17:18
01/23/18
17:18
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United sees FY18 CASM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

APTI

Apptio

$24.39

0.02 (0.08%)

17:17
01/23/18
01/23
17:17
01/23/18
17:17
Initiation
Apptio initiated at Nomura Instinet »

Apptio initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

VMW

VMware

$137.96

1.27 (0.93%)

17:16
01/23/18
01/23
17:16
01/23/18
17:16
Initiation
VMware initiated at Nomura Instinet »

Nomura starts VMware with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.